Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Stress (Psychology), Stress, Healthy Adult Female Participants, Stress, Psychologic, Stress, Psychological Cumulative, Stress, Physiological, Stress Response, Stress Levels, Stress Perception
Interventions: Intramuscular injection, OnabotulinumtoxinA (Botox®) Injections, Sodium Chloride; Procedure · Drug · Other
Lead sponsor: Center for Advanced Facial Plastic Surgery; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Sickle Cell Disease, Asthma
Interventions: Not listed
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 6 Years to 20 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida

Conditions: Breast Cancer, Obesity
Interventions: dietary intervention; Dietary Supplement
Lead sponsor: Rockefeller University; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: St Louis, Missouri • Nashville, Tennessee • Houston, Texas

Conditions: Healthy
Interventions: OEA supplement; Dietary Supplement
Lead sponsor: Nicole Stevens, PhD; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Multiple Sclerosis
Interventions: Blood Draw; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Respiratory Failure
Interventions: Enteral Vitamin D3 50,000 IU, Enteral Vitamin D3 100,000IU, Inactive substance; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Tusamitamab ravtansine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Buffalo, New York • El Paso, Texas

Conditions: Coronary Artery Disease
Interventions: statin, evolocumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Anemia
Interventions: L-NMMA, Acetylcholine; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism Disorder, Language Development Disorders, ADHD, Typical Development, Rural Health, Children, Neuroimaging, Eye Tracking, EEG, fNIRS
Interventions: Speech-Gesture combinations; Behavioral
Lead sponsor: Montana State University; Other
Eligibility: 2 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Orange, California + 10 more

Conditions: Hepatitis C, Chronic
Interventions: Liver Biopsy, Peginterferon & Ribavirin for Hepatitis C, Pre-treatment Ribavirin; Procedure · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adrenal Sufficiency
Interventions: Not listed
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 6 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Colorectal Cancer Screening
Interventions: Not listed
Lead sponsor: IntelliGeneScan, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: Romidepsin, Placebo for Romidepsin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Human Milk/Breastfeeding, Breast Pumping
Interventions: The intervention is an educational intervention using the FLANGEFits protocol in the NICU. This protocol has only been used previously in the community.; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions: Corus CAD; Diagnostic Test
Lead sponsor: CardioDx; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Phoenix, Arizona • Blue Ridge, Georgia • Youngstown, Ohio

Conditions: GERD, Gastroesophageal Reflux
Interventions: Prevacid Solutabs, Antireflux surgery; Drug · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 74 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV-1 Infection
Interventions: Vorinostat; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Belzutifan, 89Zr-DFO-girentuximab, 89Zr-DFO-girentuximab PET; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
Interventions: Mirvetuximab Soravtansine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Sarasota, Florida • Edgewood, Kentucky • Lexington, Kentucky + 4 more

Conditions: Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Interventions: casdatifan; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Impact of OnabotulinumtoxinA (BOTOX®) on Stress

Molecular Phenotyping of Asthma in Sickle Cell Disease

A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

Metabolic and Epigenetic Impact of FAAH Inhibitors and OEA

Gene Expression Profiles in Multiple Sclerosis (MS)

Vitamin D in Ventilated ICU Patients

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Rosuvastatin and Evolocumab for Coronary Artery Disease

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Nitric Oxide to Improve Blood Flow in Sickle Cell Disease

Rural Autistic Individuals - Supporting Expression

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein

Colorectal Cancer Screening Validation Study

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

Flange Fitting for NICU Pumping Parents to Explore Improved Milk Production and Satisfaction

Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma